Premium
Small Dose Anti‐Rh Therapy After First Trimester Abortion
Author(s) -
Keith Louis,
Bozorgi Nader
Publication year - 1977
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/j.1879-3479.1977.tb00682.x
Subject(s) - medicine , abortion , obstetrics , pregnancy , first trimester , gynecology , gestation , genetics , biology
The standard prophylactic dose of anti‐Rh immunoglobulin used in the United States is 300 μg. For use after spontaneous or induced abortion and diagnostic amniocentesis, this dose represents immunological “overkill”. A 50 μg dose has been effectively used for these patients in other countries but the specific products used were not equivalent to the products available in the USA. No evaluation of this 50 μg dose has been conducted in the USA. This is a pilot study of 315 patients given a 50 μg dose or a 300 μg dose of anti‐Rh immunoglobulin after first trimester abortion. No patient in either treatment group developed atypical blood group antibodies within 6 months. This finding confirms that 50 μg of the American product is protective after first trimester abortion.